The US Food and Drug Administration will now require GLP-1 drugs including Novo's Wegovy and Ozempic and Lilly's Mounjaro, Zepbound and Foundayo to carry warnings that they may increase the risk of non-arteritic anterior ischemic optic neuropathy, or NAION.
The US Food and Drug Administration will now require GLP-1 drugs including Novo's Wegovy and Ozempic and Lilly's Mounjaro, Zepbound and Foundayo to carry warnings that they may increase the risk of non-arteritic anterior ischemic optic neuropathy, or NAION.
<iframe src="https://hindustansphere.com/embed/cluster/b4f8543ef4b2a54827e13bf931d7a664ad33b7b8" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA Adds Warning Label To Obesity Drugs For Eye Condition"></iframe>
